23:16:23 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-27 Kvartalsrapport 2024-Q1
2024-05-17 X-dag ordinarie utdelning ELIC 0.00 SEK
2024-05-16 Årsstämma 2024
2024-02-20 Extra Bolagsstämma 2024
2024-02-13 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-17 X-dag ordinarie utdelning ELIC 0.00 SEK
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-16 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-22 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-08 X-dag ordinarie utdelning ELIC 0.00 SEK
2022-03-07 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-07 X-dag ordinarie utdelning ELIC 0.00 SEK
2021-04-26 Årsstämma 2021
2021-04-14 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Elicera Therapeutics är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling inom immun-onkologi för cell- och genterapier för immunbaserad cancerbehandling. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs med störst närvaro inom Sverige. Elicera Therapeutics har sitt huvudkontor i Göteborg.
2024-04-16 18:09:00

Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company's proprietary and commercially available platform iTANK, publishes the annual report for 2023.

Elicera Therapeutics annual report is now available at the webpage https://www.elicera.com.

The Annual General Meeting will be held on May 16th at 1:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

Certified Advisor

The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

The information was submitted for publication distributed through the contact person above at 18:09 CET on April 16, 2024.

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com